Hongchang International Co., Ltd

HCIL ·Healthcare, Medical Devices
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $2.9M $2.7M $79.0K $96.5K $222.7K $163.7K
Cost of Revenue $2.7M $2.6M $27.4K $30.3K $118.5K $83.6K
Gross Profit $181.6K $69.4K $51.6K $66.2K $104.2K $80.1K
Gross Margin 6.3% 2.6% 65.3% 68.6% 46.8% 48.9%
Operating Expenses
Research & Development
SG&A Expense $560.6K $538.9K $240.0K
Operating Income $-383.3K $-469.6K $-240.0K $-162.8K $-278.8K $-538.1K $-247.8K
Operating Margin -13.4% -17.5% -304.0% -168.8% -125.2% -328.8%
Interest Expense
Pretax Income $-494.7K $-444.7K $-240.0K $-163.0K $-753.1K $-540.0K $-250.3K
Income Tax Expense $-22.3K $-65.9K
Net Income $-472.4K $-378.8K $-240.0K $-163.0K $-548.4K $-488.4K $-250.3K
Net Margin -16.5% -14.2% -304.0% -169.0% -246.2% -298.4%
EPS (Basic) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
EPS (Diluted) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Shares Outstanding (Basic) 518.8M 518.8M 450.2M 431.7M 7.23B 7.23B 7.78B 7.99B
Shares Outstanding (Diluted) 518.8M 518.8M 450.2M 431.7M 7.23B 7.23B 7.78B 7.99B
Dividends Per Share
← Newer Page 1 of 2 Older →